pharmatechoutlook

BLUECATBIO: CLEAN DATA EQUALS PROMISING DRUG DISCOVERY

The pharmaceutical sector today is taking giant leaps into the future by striving to find new ways to store and manage data, put a price on medical treatments and handle endowed patients. In a market sector as competitive as this, the burden of deciding which technology to adopt for prominent pharma processes lies heavy on the shoulders of the CIOs and life science decision makers. After all, the need for discovering and developing newer drugs into the market is ever-growing. Researchers discover new drugs through means of various innovative methods, providing fresh ways to target medical products to specific sites within the body. Pharmaceutical companies need to ensure that the medications released to the public are not only safe but effectual. The process of recognizing and developing new drugs into the market is an extremely costly and time-consuming effort. On an average, it takes close to ten years for a new medicine to complete the journey from initial discovery to getting released into the marketplace, wherein the clinical trials alone take six to seven years. The average cost to research and develop each successful drug is estimated to be about $2.6 billion. In fact, the likelihood that a drug entering clinical testing will eventually get approved is only 12 percent. The overall process is thus tedious, with each drug undergoing a stringent process of uncovering, development and approval. Developing successful drugs requires immense resources working collaboratively: the best scientific minds, highly sophisticated technologies, ever-evolving manufacturing processes and complex project management. This is where Pharma Tech Outlook wishes to make an impact. This edition wishes to bring forth real-world solutions and product trends to this competitive landscape by adapting an eye-opening peer-to-peer approach. We bring to you the Top 10 Drug Discovery and Development solutions in the market today, that include insight from some of the more experienced experts in the industry, while presenting sufficient proficiency in the technology arena. Let us know your thoughts.

November 2017| View Digital Version

Table of Contents
Past Issues